Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients2018-01-17T17:04:53-05:00
Key issues in the diagnosis and treatment of multiple sclerosis Key issues in the diagnosis and treatment of multiple sclerosis2018-01-17T17:04:46-05:00
Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis2018-01-17T17:04:46-05:00
Glatiramer acetate (Copaxone®) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis Glatiramer acetate (Copaxone®) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis2018-01-17T17:04:46-05:00
Using stem cells in multiple sclerosis therapies Using stem cells in multiple sclerosis therapies2018-01-17T17:04:40-05:00
A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses2018-01-17T17:04:40-05:00
Glatiramer Acetate Therapy: The Plot Thickens Glatiramer Acetate Therapy: The Plot Thickens2018-01-17T17:04:28-05:00
A prospective, open-label treatment trial to compare the effect of IFN b-1a (Avonex), IFNb-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis A prospective, open-label treatment trial to compare the effect of IFN b-1a (Avonex), IFNb-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis2018-01-17T17:04:28-05:00
Statins as immunomodulators; Comparison with interferon-β1b in MS Statins as immunomodulators; Comparison with interferon-β1b in MS2018-01-17T17:04:28-05:00